Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis
Journal of Nephrology · 2025
DOI: 10.1007/s40620-024-02130-3 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Nephrology, 2025. Verfasst von Ernesto Calderon Martinez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Nacional Autónoma de México, Ciudad de Mexico, México. ernestocalderon.mtz@gmail.com. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Anticoagulants, Thromboembolism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic Kidney Disease (CKD) significantly increases the risk of cardiovascular diseases, including atrial fibrillation, which usually requires anticoagulant therapy. The effectiveness and safety of direct oral anticoagulants compared to vitamin K antagonists in patients with CKD remain insufficiently studied, particularly in the more advanced stages.
Methods
This systematic review, registered in PROSPERO (CRD42023410192), adhered to PRISMA guidelines and included randomized clinical trials and cohort studies comparing direct oral anticoagulants and vitamin K antagonists in CKD patients. Major databases were searched, and studies were selected based on strict inclusion criteria. A meta-analysis was performed using random-effects models.
Results
Twenty-three studies with a total of 465,673 CKD patients were included. Direct oral anticoagulants showed a significant reduction in major bleeding events compared to vitamin K antagonists (Relative Risk [RR] = 0.62, 95% Confidence Interval: 0.49–0.79, p < 0.01) and a non-significant trend toward reducing thromboembolic events (RR = 0.69, 95% Confidence Interval: 0.43–1.14, p = 0.11). Furthermore, direct oral anticoagulants were associated with a significant reduction in all-cause mortality (RR = 0.63, 95% Confidence Interval: 0.43–0.91, p = 0.02).
Conclusion
Direct oral anticoagulants may offer a safe alternative to vitamin K antagonists in CKD patients, particularly in terms of reducing bleeding risks and potentially improving survival. However, their role in preventing thromboembolic events remains uncertain, highlighting the need for further research, especially in patients with advanced CKD and kidney failure. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universidad Nacional Autónoma de México, Ciudad de Mexico, México. ernestocalderon.mtz@gmail.com.
- Universidad Nacional Autónoma de México, Ciudad de Mexico, México.
- Universidad Autónoma de Sinaloa, Sinaloa, México.
- Universidad de Monterrey, Monterrey, México.
- Univesidad Nacional de Loja, Loja, Ecuador.
- University of Texas RGV, Edinburg, TX, USA.
ORCID-Profile: Ernesto Calderon Martinez
Zitieren
APA
Calderon Martinez, E., Sanchez Cruz, C., Diarte Acosta, E. Y., Aguirre Cano, D. A., Espinosa, A. M., Othón Martínez, D., Furman, F., & Obando Vera, S. (2025). Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis. Journal of Nephrology. https://doi.org/10.1007/s40620-024-02130-3
Vancouver
Calderon Martinez E, Sanchez Cruz C, Diarte Acosta EY, Aguirre Cano DA, Espinosa AM, Othón Martínez D, et al. Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis. Journal of Nephrology. 2025. doi:10.1007/s40620-024-02130-3
BibTeX
@article{CalderonMartinez2025,
author = {Calderon Martinez, Ernesto and Sanchez Cruz, Camila and Diarte Acosta, Edna Y and Aguirre Cano, Daniel Alejandro and Espinosa, Ana Maria and Othón Martínez, Diana and Furman, Flor and Obando Vera, Sebastian},
title = {Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis},
journal = {Journal of Nephrology},
year = {2025},
doi = {10.1007/s40620-024-02130-3}
}
EUVIMED